The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Upadacitinib Induction and Maintenance Therapy for Crohn’s Disease
Open accessAbstract
BACKGROUND: Upadacitinib, an oral selective Janus kinase (JAK) inhibitor, is under investigation for the treatment of Crohn's disease. METHODS: In two phase 3 induction trials (U-EXCEL and U-EXCEED), we randomly assigned patients with moderate-to-severe Crohn's disease to receive 45 mg of upadacitinib or placebo (2:1 ratio) once daily for 12 weeks. Patients who had a clinical response to upadacitinib induction therapy were randomly assigned in the U-ENDURE maintenance trial to receive 15 mg of upadacitinib, 30 mg of upadacitinib, or placebo (1:1:1 ratio) once daily for 52 weeks. The primary end points for induction (week 12) and maintenance (week 52) were clinical remission (defined as a Crohn's Disease Activity Index score of <150 [range, 0 to 600, with higher scores indicating more severe disease activity]) and endoscopic response (defined as a decrease in the Simple Endoscopic Score for Crohn's Disease [SES-CD; range, 0 to 56, with higher scores indicating more severe disease] of >50% from baseline of the induction trial [or for patients with an SES-CD of 4 at baseline, a decrease of ≥2 points from baseline]). RESULTS: A total of 526 patients underwent randomization in U-EXCEL, 495 in U-EXCEED, and 502 in U-ENDURE. A significantly higher percentage of patients who received 45-mg upadacitinib than those who received placebo had clinical remission (in U-EXCEL, 49.5% vs. 29.1%; in U-EXCEED, 38.9% vs. 21.1%) and an endoscopic response (in U-EXCEL, 45.5% vs. 13.1%; in U-EXCEED, 34.6% vs. 3.5%) (P<0.001 for all comparisons). At week 52 in U-ENDURE, a higher percentage of patients had clinical remission with 15-mg upadacitinib (37.3%) or 30-mg upadacitinib (47.6%) than with placebo (15.1%), and a higher percentage had an endoscopic response with 15-mg upadacitinib (27.6%) or 30-mg upadacitinib (40.1%) than with placebo (7.3%) (P<0.001 for all comparisons). Herpes zoster infections occurred more frequently in the 45-mg and 30-mg upadacitinib groups than in the respective placebo groups, and hepatic disorders and neutropenia were more frequent in the 30-mg upadacitinib group than in the other maintenance groups. Gastrointestinal perforations developed in 4 patients who received 45-mg upadacitinib and in 1 patient each who received 30-mg or 15-mg upadacitinib. CONCLUSIONS: Upadacitinib induction and maintenance treatment was superior to placebo in patients with moderate-to-severe Crohn's disease. (Funded by AbbVie; U-EXCEL, U-EXCEED, and U-ENDURE ClinicalTrials.gov numbers, NCT03345849, NCT03345836, and NCT03345823.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Development of a Crohn's Disease Activity Index
Best, W. R., Becktel, J. M., Singleton, J. W., & Kern, F. (1976) · Gastroenterology · doi:10.1016/s0016-5085(76)80163-1 · Cited by 3,152
Turner, D., Ricciuto, A., Lewis, A., D’Amico, F., Dhaliwal, J., Griffiths, A. M., Bettenworth, D., Sandborn, W. J., Sands, B. E., Reinisch, W., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2020.12.031 · Cited by 2,911
Self-citationDaperno, M., D'Haens, G., Van Assche, G., Baert, F., Bulois, P., Maunoury, V., Sostegni, R., Rocca, R., Pera, A., Gevers, A., et al. (2004) · Gastrointestinal Endoscopy · doi:10.1016/s0016-5107(04)01878-4 · Cited by 1,774
Self-citationPathophysiology of Inflammatory Bowel Diseases
Chang, J. T. (2020) · New England Journal of Medicine · doi:10.1056/nejmra2002697 · Cited by 1,295
Harbord, M., Annese, V., Vavricka, S. R., Allez, M., Barreiro-de Acosta, M., Boberg, K. M., Burisch, J., De Vos, M., De Vries, A.-M., Dick, A. D., et al. (2016) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjv213 · Cited by 827
Danese, S., Vermeire, S., Zhou, W., Pangan, A. L., Siffledeen, J., Greenbloom, S., Hébuterne, X., D'Haens, G., Nakase, H., Panés, J., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00581-5 · Cited by 643
Self-citationJAK–STAT pathway targeting for the treatment of inflammatory bowel disease
Salas, A., Hernandez-Rocha, C., Duijvestein, M., Faubion, W., McGovern, D., Vermeire, S., Vetrano, S., & Vande Casteele, N. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0273-0 · Cited by 635
Genovese, M. C., Fleischmann, R., Combe, B., Hall, S., Rubbert-Roth, A., Zhang, Y., Zhou, Y., Mohamed, M.-E. F., Meerwein, S., & Pangan, A. L. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31116-4 · Cited by 422
Self-citationReich, K., Teixeira, H. D., de Bruin-Weller, M., Bieber, T., Soong, W., Kabashima, K., Werfel, T., Zeng, J., Huang, X., Hu, X., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00589-4 · Cited by 402
In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)
Parmentier, J. M., Voss, J., Graff, C., Schwartz, A., Argiriadi, M., Friedman, M., Camp, H. S., Padley, R. J., George, J. S., Hyland, D., et al. (2018) · BMC Rheumatology · doi:10.1186/s41927-018-0031-x · Cited by 390
Cited by
Dolinger, M., Torres, J., & Vermeire, S. (2024) · The Lancet · doi:10.1016/s0140-6736(23)02586-2 · Cited by 580
ECCO Guidelines on Therapeutics in Crohn’s Disease: Medical Treatment
Gordon, H., Minozzi, S., Kopylov, U., Verstockt, B., Chaparro, M., Buskens, C., Warusavitarne, J., Agrawal, M., Allocca, M., Atreya, R., et al. (2024) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjae091 · Cited by 388
Metadata
- Authors
- Loftus, E. V., Panés, J., Lacerda, A. P., Peyrin-Biroulet, L., D’Haens, G., Panaccione, R., Reinisch, W., Louis, E., Chen, M., Nakase, H., Begun, J., Boland, B. S., Phillips, C., Mohamed, M.-E. F., Liu, J., Geng, Z., Feng, T., Dubcenco, E., & Colombel, J.-F.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-05-25
- Volume
- 388
- Issue
- 21
- Pages
- 1966-1980
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4377966457
- Cited by
- 483
- References
- 21
- FWCI
- 70.76
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Upadacitinib Induction and Maintenance Therapy for Crohn’s Disease. https://app.cochat.ai/papers/10.1056/nejmoa2212728
- The paper
- Loftus, E. V., Panés, J., Lacerda, A. P., Peyrin-Biroulet, L., D’Haens, G., Panaccione, R., Reinisch, W., Louis, E., Chen, M., Nakase, H., Begun, J., Boland, B. S., Phillips, C., Mohamed, M.-E. F., Liu, J., Geng, Z., Feng, T., Dubcenco, E., & Colombel, J.-F. (2023). Upadacitinib Induction and Maintenance Therapy for Crohn’s Disease. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2212728
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.